Leverone Jason A., CFO of OnKure Therapeutics ($OKUR), made five open market sales of company shares over the past year, totaling $11,600. His most recent sale occurred on December 22, 2025. These transactions rank 11,241st out of 11,678 insiders in the database by sale value, well below the average of $8.6 million across 6.4 transactions per insider. He reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | A | Employee Stock Option (right to buy) | 110000 | $0.00 | 110,000.0000 | 13,530,892 | 9999.99% | 0.81% |
| March 23, 2026 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | S | Class A Common Stock | 301 | $4.16 | 16,000.0000 | 13,530,892 | 1.85% | 0.00% |
| Dec. 22, 2025 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | S | Class A Common Stock | 302 | $2.97 | 16,301.0000 | 13,530,892 | 1.82% | 0.00% |
| Sept. 22, 2025 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | S | Class A Common Stock | 303 | $2.62 | 12,603.0000 | 3,447,071 | 2.35% | 0.01% |
| June 23, 2025 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | S | Class A Common Stock | 303 | $2.38 | 12,906.0000 | 3,447,071 | 2.29% | 0.01% |
| April 7, 2025 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | S | Class A Common Stock | 1844 | $2.67 | 13,209.0000 | 3,447,071 | 12.25% | 0.05% |
| April 4, 2025 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | S | Class A Common Stock | 1278 | $3.33 | 15,053.0000 | 3,447,071 | 7.83% | 0.04% |
| Jan. 27, 2025 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | A | Employee Stock Option (right to buy) | 65000 | $0.00 | 65,000.0000 | 3,447,071 | 9999.99% | 1.89% |
| Oct. 4, 2024 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | A | Employee Stock Option (right to buy) | 5781 | $0.00 | 5,781.0000 | 316,142 | 9999.99% | 1.83% |
| Oct. 4, 2024 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | A | Class A Common Stock | 16331 | $0.00 | 16,331.0000 | 316,142 | 9999.99% | 5.17% |
| Oct. 4, 2024 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | A | Employee Stock Option (right to buy) | 5322 | $0.00 | 5,322.0000 | 316,142 | 9999.99% | 1.68% |
| Oct. 4, 2024 | OnKure Therapeutics, Inc. | $OKUR | Leverone Jason A. | Chief Financial Officer | A | Employee Stock Option (right to buy) | 130611 | $0.00 | 130,611.0000 | 316,142 | 9999.99% | 41.31% |